tradingkey.logo
tradingkey.logo
Search

Organogenesis Holdings Inc

ORGO
Add to Watchlist
2.360USD
-0.080-3.28%
Close 07/02, 13:00ETQuotes delayed by 15 min
303.67MMarket Cap
LossP/E TTM

TradingKey Stock Score of Organogenesis Holdings Inc

Currency: USD Updated: 2026-07-02

Key Insights

Organogenesis Holdings Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 81 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 3.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Organogenesis Holdings Inc's Score

Industry at a Glance

Industry Ranking
81 / 387
Overall Ranking
183 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Organogenesis Holdings Inc Highlights

StrengthsRisks
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.25% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 564.17M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is -21.36, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 70.97M shares, decreasing 7.21% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 56.65K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.32.

Analyst Rating

Based on 2 analysts
Hold
Current Rating
3.000
Target Price
+22.95%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Organogenesis Holdings Inc?

The TradingKey Stock Score provides a comprehensive assessment of Organogenesis Holdings Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Organogenesis Holdings Inc’s performance and outlook.

How do we generate the financial health score of Organogenesis Holdings Inc?

To generate the financial health score of Organogenesis Holdings Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Organogenesis Holdings Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Organogenesis Holdings Inc.

How do we generate the company valuation score of Organogenesis Holdings Inc?

To generate the company valuation score of Organogenesis Holdings Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Organogenesis Holdings Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Organogenesis Holdings Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Organogenesis Holdings Inc.

How do we generate the earnings forecast score of Organogenesis Holdings Inc?

To calculate the earnings forecast score of Organogenesis Holdings Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Organogenesis Holdings Inc’s future.

How do we generate the price momentum score of Organogenesis Holdings Inc?

When generating the price momentum score for Organogenesis Holdings Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Organogenesis Holdings Inc’s prices. A higher score indicates a more stable short-term price trend for Organogenesis Holdings Inc.

How do we generate the institutional confidence score of Organogenesis Holdings Inc?

To generate the institutional confidence score of Organogenesis Holdings Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Organogenesis Holdings Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Organogenesis Holdings Inc.

How do we generate the risk management score of Organogenesis Holdings Inc?

To assess the risk management score of Organogenesis Holdings Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Organogenesis Holdings Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Organogenesis Holdings Inc.